Back to Search
Start Over
Postinfectious SARS-CoV-2 Opsoclonus-Myoclonus-Ataxia Syndrome.
- Source :
-
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society [J Neuroophthalmol] 2022 Jun 01; Vol. 42 (2), pp. 251-255. Date of Electronic Publication: 2021 Dec 30. - Publication Year :
- 2022
-
Abstract
- Background: The opsoclonus-myoclonus-ataxia syndrome (OMAS) represents a pathophysiology and diagnostic challenge. Although the diverse etiologies likely share a common mechanism to generate ocular, trunk, and limb movements, the underlying cause may be a paraneoplastic syndrome, as the first sign of cancer, or may be a postinfectious complication, and thus, the outcome depends on identifying the trigger mechanism. A recent hypothesis suggests increased GABAA receptor sensitivity in the olivary-oculomotor vermis-fastigial nucleus-premotor saccade burst neuron circuit in the brainstem. Therefore, OMAS management will focus on immunosuppression and modulation of GABAA hypersensitivity with benzodiazepines.<br />Methods: We serially video recorded the eye movements at the bedside of 1 patient with SARS-CoV-2-specific Immunoglobulin G (IgG) serum antibodies, but twice-negative nasopharyngeal reverse transcription polymerase chain reaction (RT-PCR). We tested cerebrospinal fluid (CSF), serum, and nasopharyngeal samples. After brain MRI and chest, abdomen, and pelvis CT scans, we treated our patient with clonazepam and high-dose Solu-MEDROL, followed by a rituximab infusion after her formal eye movement analysis 10 days later.<br />Results: The recordings throughout her acute illness demonstrated different eye movement abnormalities. While on high-dose steroids and clonazepam, she initially had macrosaccadic oscillations, followed by brief ocular flutter during convergence the next day; after 10 days, she had bursts of opsoclonus during scotopic conditions with fixation block but otherwise normal eye movements. Concern for a suboptimal response to high-dose Solu-MEDROL motivated an infusion of rituximab, which induced remission. An investigation for a paraneoplastic etiology was negative. CSF testing showed elevated neuron-specific enolase. Serum IgG to Serum SARS-CoV2 IgG was elevated with negative RT-PCR nasopharyngeal testing.<br />Conclusion: A recent simulation model of macrosaccadic oscillations and OMAS proposes a combined pathology of brainstem and cerebellar because of increased GABAA receptor sensitivity. In this case report, we report 1 patient with elevated CSF neuronal specific enolase, macrosaccadic oscillations, ocular flutter, and OMAS as a SARS-CoV-2 postinfectious complication. Opsoclonus emerged predominantly with fixation block and suppressed with fixation, providing support to modern theories on the mechanism responsible for these ocular oscillations involving cerebellar-brainstem pathogenesis.<br />Competing Interests: The authors report no conflicts of interest.<br /> (Copyright © 2021 by North American Neuro-Ophthalmology Society.)
- Subjects :
- Clonazepam therapeutic use
Female
Humans
Immunoglobulin G
Methylprednisolone Hemisuccinate therapeutic use
RNA, Viral therapeutic use
Receptors, GABA-A therapeutic use
Rituximab therapeutic use
SARS-CoV-2
COVID-19 complications
Cerebellar Ataxia complications
Ocular Motility Disorders diagnosis
Ocular Motility Disorders drug therapy
Ocular Motility Disorders etiology
Opsoclonus-Myoclonus Syndrome diagnosis
Opsoclonus-Myoclonus Syndrome drug therapy
Opsoclonus-Myoclonus Syndrome etiology
Subjects
Details
- Language :
- English
- ISSN :
- 1536-5166
- Volume :
- 42
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
- Publication Type :
- Academic Journal
- Accession number :
- 34974489
- Full Text :
- https://doi.org/10.1097/WNO.0000000000001498